Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption

Página do item simplificado
dc.contributor.authorKalmar, E. M. N.
dc.contributor.authorSanabani, S. S. [UNIFESP]
dc.contributor.authorCosta, A. Charlys da [UNIFESP]
dc.contributor.authorFerreira, S.
dc.contributor.authorBarreto, C. C.
dc.contributor.authorChen, S.
dc.contributor.authorSabino, E. C.
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionSTD AIDS Reference & Training Ctr
dc.contributor.institutionFundacao Prosangue
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionSan Francisco Dept Publ Hlth
dc.date.accessioned2016-01-24T14:17:54Z
dc.date.available2016-01-24T14:17:54Z
dc.date.issued2012-02-01
dc.description.abstractMost of the antiretroviral (ARV) studies in Brazil have been reported in treatment-experienced and naive patients rather than in the setting of treatment interruption (TI). in this study, we analysed reasons given for TI and resistance mutations occurring in 150 HIV-1-infected patients who underwent TI. of the patients analysed, 110 (73.3%) experienced TI following medical advice, while the remaining patients stopped antiretroviral therapy (ART) of their own accord. the main justifications for TI were: ARV-related toxicities (38.7%), good laboratory parameters (30%) and poor adherence (20%). DNA sequencing of the partial pol gene was successful in 137 (91.3%) patients, of whom 38 (27.7%) presented mutations conferring ARV resistance. A higher viral load prior to TI correlated with drug resistance (P < 0.05). Our results demonstrate that there are diverse rationales for TI and that detection of resistant strains during TI most likely indicates a fitter virus than the wild type. High viral loads coupled with unprotected sex in this group could increase the likelihood of transmission of drug-resistant virus. Thus, treating physicians should be alerted to this problem when the use of ARVs is interrupted.en
dc.description.affiliationUniv São Paulo, Fac Med, Dept Infect Dis, São Paulo, Brazil
dc.description.affiliationSTD AIDS Reference & Training Ctr, São Paulo, Brazil
dc.description.affiliationFundacao Prosangue, Hemoctr, BR-05403000 São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Translat Med, São Paulo, Brazil
dc.description.affiliationSan Francisco Dept Publ Hlth, San Francisco, CA USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Translat Med, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIDFAPESP: 2002/04016-4
dc.format.extent120-125
dc.identifierhttp://dx.doi.org/10.1258/ijsa.2011.011124
dc.identifier.citationInternational Journal of Std & Aids. London: Royal Soc Medicine Press Ltd, v. 23, n. 2, p. 120-125, 2012.
dc.identifier.doi10.1258/ijsa.2011.011124
dc.identifier.issn0956-4624
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/34616
dc.identifier.wosWOS:000303096200009
dc.language.isoeng
dc.publisherRoyal Soc Medicine Press Ltd
dc.relation.ispartofInternational Journal of Std & Aids
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjecthuman immunodeficiency virusen
dc.subjectHIVen
dc.subjectantiretroviral therapyen
dc.subjectresistanceen
dc.subjecttreatment interruptionen
dc.titleEvaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruptionen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral